This study focuses on testing a new treatment called CS-101 for people with Sickle Cell Disease. Sickle Cell Disease affects the red blood cells, causing pain and other health problems. CS-101 is a special type of cell therapy that aims to increase a type of hemoglobin (HbF) that helps carry oxygen in the blood, potentially offering a cure without needing a donor match or worrying about graft-versus-host disease.
- The study is open to individuals aged 12 to 35 who meet certain health criteria.
- Participants must agree to regular check-ups and follow the study guidelines.
- Pregnant women and those with severe liver or kidney problems cannot join this study.
Participants will receive the treatment and be monitored to see how well it works and if it is safe. This study does not involve a comparison group, meaning all participants receive the treatment. If you fit the criteria and are interested, your participation could help advance treatments for sickle cell disease.
How understandable was the trial content above?
Hard to understand
Easy to understand